Benzinga | Apr 22, 2021 07:30AM EDT

Axcella To Present At Oral Presentation at Digestive Disease Week 2021 May 23rd

Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the following upcoming oral presentation at the DDW 2021 regarding AXA1665, the company's product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE):

* Title: A Novel, Precision-Engineered Amino Acid Composition, AXA1665, is Safe, Well-Tolerated and Improves Neurocognition and Physical Function in Child-Pugh A and B Subjects Abstract Number: 848 Presenter: Dr. Arun Sanyal, Professor in the Virginia Commonwealth University (VCU) Department of Internal Medicine and Education Core Director in the VCU Center for Clinical and Translational Research Session: #4450 Portal Hypertension Date/Time: Sunday, May 23rd from 5:45-6:00 p.m. ET DDW 2021 is being held virtually from May 21 to 23, 2021. Abstracts are expected to appear on DDW's website in late April and in the May online supplement to Gastroenterology. ePosters and ePapers will be made available on this website during the congress. DDW is the world's leading educational forum for clinicians, researchers, students and trainees working in gastroenterology, hepatology, GI endoscopy, gastrointestinal surgery and related fields.